American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.

Abstract

OBJECTIVES:

Meglumine antimoniate (MA; Glucantime®), the 80-year-old first-line systemic treatment for all forms of American tegumentary leishmaniasis (ATL) caused by Leishmania (Viannia) braziliensis, Leishmania (Viannia) guyanensis and Leishmania (Leishmania) amazonensis, is highly toxic, presents adverse side-effects and may not attain clinical and parasitological cure. This critical review examines the necessity for intramuscular/intravenous administration of MA, the alternatives to this approach, and the possibilities of developing affordable, accessible and non-toxic drugs or new delivery methods.

METHOD:

PubMed searches were performed using the terms 'cutaneous leishmaniasis' or 'American tegumentary leishmaniasis' in combination with 'meglumine antimoniate' or 'N-methyl glucamine' or 'drug repositioning' or 'nanotechnology'. Searches covered a period of 20 years of peer reviewed journals and technical bulletins. We explored the mode of action, pharmacokinetics, toxicity and efficacy of MA, evaluated the progress of ATL therapy in Brazil, and examined the potential of drug repositioning and nanotechnology in accelerating the introduction and/or optimisation of an alternative treatment.

RESULTS:

The evidence suggests that ATL therapy will continue to rely on systemic MA in the foreseeable future even though an intralesional subcutaneous route has evolved over the last 10 years. The chances of developing a novel drug for ATL or a new mode of delivery of MA are low. While MA nanocarriers afford a promising approach, this technology is still in its infancy. A more immediate solution would be the production of a bioequivalent of miltefosine, an efficacious oral agent no longer protected by patent.

CONCLUSION:

Development of a contemporary treatment requires governmental commitment in bringing together private and public sectors.

• Authors: Sílvia H Carvalho, Frédéric Frézard, Neila P Pereira, Alexandre S Moura, Lucinéia M Q C Ramos, Gabriel B Carvalho, Manoel O C Rocha
• Journal: Tropical medicine & international health : TM & IH (Trop Med Int Health) Vol. 24 Issue 4 Pg. 380-391 (04 2019) ISSN: 1365-3156 [Electronic] England
• PMID: 30681239 (Publication Type: Journal Article, Review)
• Copyright: © 2019 John Wiley & Sons Ltd.

Chemical References

• Antiprotozoal Agents
• Phosphorylcholine
• miltefosine
• Meglumine Antimoniate

Topics

• Antiprotozoal Agents (administration & dosage, adverse effects, therapeutic use)
• Brazil
• Humans
• Leishmania braziliensis
• Leishmania guyanensis
• Leishmaniasis, Cutaneous (drug therapy, parasitology)
• Meglumine Antimoniate (administration & dosage, adverse effects, therapeutic use)
• Patents as Topic
• Phosphorylcholine (administration & dosage, analogs & derivatives, therapeutic use)